Fas-related apoptosis in gastric adenocarcinoma

Oncology Reports

Volumn 10, Issue 1, 2003, Pages 57-63

  Lim, Sung Chul ^a  

^a Chosun University   (South Korea)

Author keywords

Adenocarcinoma; Apoptosis; Fas; FasL; Lymphocytes; Stomach; Tumor infiltrating

Indexed keywords

CD45 ANTIGEN; FAS ANTIGEN; FAS LIGAND; FASLG PROTEIN, HUMAN; LIGAND; MEMBRANE PROTEIN;

ADENOCARCINOMA; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER STAGING; CONFOCAL MICROSCOPY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GASTRECTOMY; HUMAN; METABOLISM; MIDDLE AGED; NICK END LABELING; PATHOLOGY; STOMACH TUMOR; TUMOR ASSOCIATED LEUKOCYTE;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, CD45; ANTIGENS, CD95; APOPTOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FLUORESCENT ANTIBODY TECHNIQUE; GASTRECTOMY; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; LIGANDS; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE GLYCOPROTEINS; MICROSCOPY, CONFOCAL; MIDDLE AGED; NEOPLASM STAGING; STOMACH NEOPLASMS;

EID: 0842310014     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.1.57     Document Type: Article

References (37)

1. Korsmeyer SJ: bcl-2 initiated a new category of oncogenesis: regulator of cell death. Blood 80: 879-886, 1992.
2. Bishop JM: The molecular genetics of cancer. Science 235: 305-311, 1987.
3. Sager R: Tumor suppressor gene: the puzzle and promise. Science 246: 1406-1412, 1989.
4. O'Connell J, O'Sullivan GC, Collins JK and Shanahan F: The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184: 1075-1082, 1996.
5. Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK and Shanahan F: The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 160: 5669-5675, 1998. (Pubitemid 28267863)
6. Bennett MW, O'Connell J, O'Sullivan GC, Roche D, Brady C, Kelly J, et al: Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut 44: 156-162, 1999. (Pubitemid 29119356)
7. Inoue H, Mori M, Honda M, Li J, Shbuta K, Mimori K, et al: The expression of tumor rejection-antigen MAGE genes in human gastric carcinoma. Gastroenterology 109: 1522-1525, 1995.
8. Hoshino T, Seki N, Kikuchi M, Kuramoto T, Iwamoto O, Kodama I, et al: HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer. Int J Cancer 70: 631-638, 1997. (Pubitemid 27158439)
9. Maehara Y, Tomisaki S and Oda S: Lymph node metastasis and relation to tumor growth potential and local immune response in advanced gastric cancer. Int J Cancer 74: 224-228, 1997. (Pubitemid 27234515)
10. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK and Shanahan F: The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol Med 3: 294-300, 1997. (Pubitemid 27295100)
11. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, et al: Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 274: 1363-1366, 1996. (Pubitemid 26391458)
12. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, et al: Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion? Nat Med 2: 1361-1366, 1996.
13. Shiraki K, Tsuji N, Shioda T, Isselbacher, KJ and Takahashi H: Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 94: 6420-6425, 1997.
14. Nagata S and Golstein P: The Fas death factor. Science 267: 1449-1456, 1995.
15. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, et al: Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81: 935-946, 1995.
16. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, et al: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268: 1347-1349, 1995.
17. Debatin KM and Krammer PH: Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a bcl-2 independent anti-apoptotic program. Leukemia 9: 815-820, 1995.
18. Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K and Kishimoto T: Myeloma cell express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 85: 757-764, 1995.
19. Owen-Schaub LB, Radinsky R, Kruzel E, Berry K and Yonehara S: Anti-Fas on non-hematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res 54: 1580-1586, 1994. (Pubitemid 24106426)
20. Lauren P: The two histological main types of gastric carcinoma. Diffuse and so-called intestinal type carcinoma. Acta Pathol Microbiol Scand 64: 31-49, 1965.
21. Beahrs OH, Henson DE, Hutter RVP and Kennedy BJ: Manual for staging of cancer. In: American Joint Committee on Cancer (eds). 4th edition. Lippincott, Philadelphia, 1992.
22. Wright SC, Zhong J and Larrick JW: Inhibition of apoptosis as a mechanism of tumor promotion. FASEB J 8: 654-660, 1994. (Pubitemid 24198683)
23. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, et al: Human lung carcinomas express Fas ligand. Cancer Res 57: 1007-1012, 1997. (Pubitemid 27138590)
24. Saas P, Walker PR, Hahne M, Quiquerez AL, Perrin G, French L, et al: Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 99: 1173-1178, 1997. (Pubitemid 27142752)
25. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E and Kosma VM: Prognostic value of tumor-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 182: 318-324, 1997. (Pubitemid 27285785)
26. Mulder WMC, Bloemena E, Stukart MJ, Kummer JA, Wagstaff J and Scheper RJ: T cell receptor-ζ and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut 40: 113-119, 1997. (Pubitemid 27079762)
27. Zhang H, Yang Y, Horton JL, Samoilova EB, Judge TA, Turka LA, et al: Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J Clin Invest 100: 1951-1957, 1997. (Pubitemid 27459348)
28. Arai H, Chan SY, Bishop DK and Nabel GJ: Inhibition of the alloantibody response by CD95 ligand. Nat Med 3: 843-848, 1997. (Pubitemid 27353442)
29. Lau HT and Stoeckert CJ: FasL: too much of a good thing? Nat Med 3: 727-728, 1997. (Pubitemid 27298713)
30. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S and Henne C: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69: 415-429, 1993. (Pubitemid 23335841)
31. Vollmers HP, Dammrich J, Hensel F, Ribbert H, Meyer-Bahlburg A, Ufken-Gaul T, et al: Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma. Cancer 79: 433-440, 1997. (Pubitemid 27051765)
32. Wright PA, Quirke P, Attanoos R and Williams GT: Molecular pathology of gastric carcinoma: progress and prospects. Hum Pathol 23: 848-859, 1992.
33. Tahara E: Molecular mechanism of stomach carcinogenesis. J Cancer Res Clin Oncol 119: 265-272, 1993.
34. Fukunaga M, Monden T, Nakashini H, Ohue M, Fukuda K, Tomita N, et al: Immunohistochemical study of p53 in gastric cancer. Am J Clin Pathol 101: 177-180, 1994. (Pubitemid 24061444)
35. Sugamura K, Makino M and Shirai H: Enhanced induction of apoptosis of human gastric carcinoma cells after preoperative treatment with 5-fluorouracil. Cancer 79: 12-17, 1997. (Pubitemid 26425502)
36. Vollmers HP, Dammrich J, Ribbert H, Wozniak E and Muller-Hermelink HK: Apoptosis of stomach carcinoma cells induced by a human monoclonal antibody. Cancer 76: 550-558, 1995.
37. Trauth BC, Klas C, Peters AMJ, Matzku S, Moller P and Falk W: Monoclonal antibody mediated tumor regression by induction of apoptosis. Science 245: 301-305, 1989. (Pubitemid 19196649)